Global Oral Drugs for Benign Prostatic Hyperplasia Supply, Demand and Key Producers, 2023-2029

Page: 112

Published Date: 04 Feb 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

The global Oral Drugs for Benign Prostatic Hyperplasia market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

This report studies the global Oral Drugs for Benign Prostatic Hyperplasia production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Oral Drugs for Benign Prostatic Hyperplasia, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Oral Drugs for Benign Prostatic Hyperplasia that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Oral Drugs for Benign Prostatic Hyperplasia total production and demand, 2018-2029, (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia total production value, 2018-2029, (USD Million)
Global Oral Drugs for Benign Prostatic Hyperplasia production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Oral Drugs for Benign Prostatic Hyperplasia domestic production, consumption, key domestic manufacturers and share
Global Oral Drugs for Benign Prostatic Hyperplasia production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Oral Drugs for Benign Prostatic Hyperplasia production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Oral Drugs for Benign Prostatic Hyperplasia market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Viatris, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Oral Drugs for Benign Prostatic Hyperplasia market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Oral Drugs for Benign Prostatic Hyperplasia Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Oral Drugs for Benign Prostatic Hyperplasia Market, Segmentation by Type
    Alpha Blockers
    5-alpha Reductase Inhibitors
    Others

Global Oral Drugs for Benign Prostatic Hyperplasia Market, Segmentation by Application
    Hospitals
    Drugstores
    Others

Companies Profiled:
    Eli Lilly
    GlaxoSmithKline
    Astellas Pharma
    Sanofi
    Pfizer
    Abbott
    Allergan
    TEVA
    Viatris
    Novartis
    Merck

Key Questions Answered
1. How big is the global Oral Drugs for Benign Prostatic Hyperplasia market?
2. What is the demand of the global Oral Drugs for Benign Prostatic Hyperplasia market?
3. What is the year over year growth of the global Oral Drugs for Benign Prostatic Hyperplasia market?
4. What is the production and production value of the global Oral Drugs for Benign Prostatic Hyperplasia market?
5. Who are the key producers in the global Oral Drugs for Benign Prostatic Hyperplasia market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Oral Drugs for Benign Prostatic Hyperplasia Introduction
    1.2 World Oral Drugs for Benign Prostatic Hyperplasia Supply & Forecast
        1.2.1 World Oral Drugs for Benign Prostatic Hyperplasia Production Value (2018 & 2022 & 2029)
        1.2.2 World Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2029)
        1.2.3 World Oral Drugs for Benign Prostatic Hyperplasia Pricing Trends (2018-2029)
    1.3 World Oral Drugs for Benign Prostatic Hyperplasia Production by Region (Based on Production Site)
        1.3.1 World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Region (2018-2029)
        1.3.2 World Oral Drugs for Benign Prostatic Hyperplasia Production by Region (2018-2029)
        1.3.3 World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Region (2018-2029)
        1.3.4 North America Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2029)
        1.3.5 Europe Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2029)
        1.3.6 China Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2029)
        1.3.7 Japan Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Oral Drugs for Benign Prostatic Hyperplasia Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Oral Drugs for Benign Prostatic Hyperplasia Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Oral Drugs for Benign Prostatic Hyperplasia Demand (2018-2029)
    2.2 World Oral Drugs for Benign Prostatic Hyperplasia Consumption by Region
        2.2.1 World Oral Drugs for Benign Prostatic Hyperplasia Consumption by Region (2018-2023)
        2.2.2 World Oral Drugs for Benign Prostatic Hyperplasia Consumption Forecast by Region (2024-2029)
    2.3 United States Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029)
    2.4 China Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029)
    2.5 Europe Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029)
    2.6 Japan Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029)
    2.7 South Korea Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029)
    2.8 ASEAN Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029)
    2.9 India Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029)

3 World Oral Drugs for Benign Prostatic Hyperplasia Manufacturers Competitive Analysis
    3.1 World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Manufacturer (2018-2023)
    3.2 World Oral Drugs for Benign Prostatic Hyperplasia Production by Manufacturer (2018-2023)
    3.3 World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Manufacturer (2018-2023)
    3.4 Oral Drugs for Benign Prostatic Hyperplasia Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Oral Drugs for Benign Prostatic Hyperplasia Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Oral Drugs for Benign Prostatic Hyperplasia in 2022
        3.5.3 Global Concentration Ratios (CR8) for Oral Drugs for Benign Prostatic Hyperplasia in 2022
    3.6 Oral Drugs for Benign Prostatic Hyperplasia Market: Overall Company Footprint Analysis
        3.6.1 Oral Drugs for Benign Prostatic Hyperplasia Market: Region Footprint
        3.6.2 Oral Drugs for Benign Prostatic Hyperplasia Market: Company Product Type Footprint
        3.6.3 Oral Drugs for Benign Prostatic Hyperplasia Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Oral Drugs for Benign Prostatic Hyperplasia Production Value Comparison
        4.1.1 United States VS China: Oral Drugs for Benign Prostatic Hyperplasia Production Value Comparison (2018 & 2022 & 2029)
        4.1.2 United States VS China: Oral Drugs for Benign Prostatic Hyperplasia Production Value Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States VS China: Oral Drugs for Benign Prostatic Hyperplasia Production Comparison
        4.2.1 United States VS China: Oral Drugs for Benign Prostatic Hyperplasia Production Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Oral Drugs for Benign Prostatic Hyperplasia Production Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States VS China: Oral Drugs for Benign Prostatic Hyperplasia Consumption Comparison
        4.3.1 United States VS China: Oral Drugs for Benign Prostatic Hyperplasia Consumption Comparison (2018 & 2022 & 2029)
        4.3.2 United States VS China: Oral Drugs for Benign Prostatic Hyperplasia Consumption Market Share Comparison (2018 & 2022 & 2029)
    4.4 United States Based Oral Drugs for Benign Prostatic Hyperplasia Manufacturers and Market Share, 2018-2023
        4.4.1 United States Based Oral Drugs for Benign Prostatic Hyperplasia Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Value (2018-2023)
        4.4.3 United States Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2023)
    4.5 China Based Oral Drugs for Benign Prostatic Hyperplasia Manufacturers and Market Share
        4.5.1 China Based Oral Drugs for Benign Prostatic Hyperplasia Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Value (2018-2023)
        4.5.3 China Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2023)
    4.6 Rest of World Based Oral Drugs for Benign Prostatic Hyperplasia Manufacturers and Market Share, 2018-2023
        4.6.1 Rest of World Based Oral Drugs for Benign Prostatic Hyperplasia Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Value (2018-2023)
        4.6.3 Rest of World Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2023)

5 Market Analysis by Type
    5.1 World Oral Drugs for Benign Prostatic Hyperplasia Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Alpha Blockers
        5.2.2 5-alpha Reductase Inhibitors
        5.2.3 Others
    5.3 Market Segment by Type
        5.3.1 World Oral Drugs for Benign Prostatic Hyperplasia Production by Type (2018-2029)
        5.3.2 World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Type (2018-2029)
        5.3.3 World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Oral Drugs for Benign Prostatic Hyperplasia Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Hospitals
        6.2.2 Drugstores
        6.2.3 Others
    6.3 Market Segment by Application
        6.3.1 World Oral Drugs for Benign Prostatic Hyperplasia Production by Application (2018-2029)
        6.3.2 World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Application (2018-2029)
        6.3.3 World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Application (2018-2029)

7 Company Profiles
    7.1 Eli Lilly
        7.1.1 Eli Lilly Details
        7.1.2 Eli Lilly Major Business
        7.1.3 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        7.1.4 Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.1.5 Eli Lilly Recent Developments/Updates
        7.1.6 Eli Lilly Competitive Strengths & Weaknesses
    7.2 GlaxoSmithKline
        7.2.1 GlaxoSmithKline Details
        7.2.2 GlaxoSmithKline Major Business
        7.2.3 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        7.2.4 GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.2.5 GlaxoSmithKline Recent Developments/Updates
        7.2.6 GlaxoSmithKline Competitive Strengths & Weaknesses
    7.3 Astellas Pharma
        7.3.1 Astellas Pharma Details
        7.3.2 Astellas Pharma Major Business
        7.3.3 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        7.3.4 Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.3.5 Astellas Pharma Recent Developments/Updates
        7.3.6 Astellas Pharma Competitive Strengths & Weaknesses
    7.4 Sanofi
        7.4.1 Sanofi Details
        7.4.2 Sanofi Major Business
        7.4.3 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        7.4.4 Sanofi Oral Drugs for Benign Prostatic Hyperplasia Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.4.5 Sanofi Recent Developments/Updates
        7.4.6 Sanofi Competitive Strengths & Weaknesses
    7.5 Pfizer
        7.5.1 Pfizer Details
        7.5.2 Pfizer Major Business
        7.5.3 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        7.5.4 Pfizer Oral Drugs for Benign Prostatic Hyperplasia Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.5.5 Pfizer Recent Developments/Updates
        7.5.6 Pfizer Competitive Strengths & Weaknesses
    7.6 Abbott
        7.6.1 Abbott Details
        7.6.2 Abbott Major Business
        7.6.3 Abbott Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        7.6.4 Abbott Oral Drugs for Benign Prostatic Hyperplasia Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.6.5 Abbott Recent Developments/Updates
        7.6.6 Abbott Competitive Strengths & Weaknesses
    7.7 Allergan
        7.7.1 Allergan Details
        7.7.2 Allergan Major Business
        7.7.3 Allergan Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        7.7.4 Allergan Oral Drugs for Benign Prostatic Hyperplasia Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.7.5 Allergan Recent Developments/Updates
        7.7.6 Allergan Competitive Strengths & Weaknesses
    7.8 TEVA
        7.8.1 TEVA Details
        7.8.2 TEVA Major Business
        7.8.3 TEVA Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        7.8.4 TEVA Oral Drugs for Benign Prostatic Hyperplasia Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.8.5 TEVA Recent Developments/Updates
        7.8.6 TEVA Competitive Strengths & Weaknesses
    7.9 Viatris
        7.9.1 Viatris Details
        7.9.2 Viatris Major Business
        7.9.3 Viatris Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        7.9.4 Viatris Oral Drugs for Benign Prostatic Hyperplasia Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.9.5 Viatris Recent Developments/Updates
        7.9.6 Viatris Competitive Strengths & Weaknesses
    7.10 Novartis
        7.10.1 Novartis Details
        7.10.2 Novartis Major Business
        7.10.3 Novartis Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        7.10.4 Novartis Oral Drugs for Benign Prostatic Hyperplasia Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.10.5 Novartis Recent Developments/Updates
        7.10.6 Novartis Competitive Strengths & Weaknesses
    7.11 Merck
        7.11.1 Merck Details
        7.11.2 Merck Major Business
        7.11.3 Merck Oral Drugs for Benign Prostatic Hyperplasia Product and Services
        7.11.4 Merck Oral Drugs for Benign Prostatic Hyperplasia Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.11.5 Merck Recent Developments/Updates
        7.11.6 Merck Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Oral Drugs for Benign Prostatic Hyperplasia Industry Chain
    8.2 Oral Drugs for Benign Prostatic Hyperplasia Upstream Analysis
        8.2.1 Oral Drugs for Benign Prostatic Hyperplasia Core Raw Materials
        8.2.2 Main Manufacturers of Oral Drugs for Benign Prostatic Hyperplasia Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Oral Drugs for Benign Prostatic Hyperplasia Production Mode
    8.6 Oral Drugs for Benign Prostatic Hyperplasia Procurement Model
    8.7 Oral Drugs for Benign Prostatic Hyperplasia Industry Sales Model and Sales Channels
        8.7.1 Oral Drugs for Benign Prostatic Hyperplasia Sales Model
        8.7.2 Oral Drugs for Benign Prostatic Hyperplasia Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Region (2018, 2022 and 2029) & (USD Million)
    Table 2. World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Region (2018-2023) & (USD Million)
    Table 3. World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Region (2024-2029) & (USD Million)
    Table 4. World Oral Drugs for Benign Prostatic Hyperplasia Production Value Market Share by Region (2018-2023)
    Table 5. World Oral Drugs for Benign Prostatic Hyperplasia Production Value Market Share by Region (2024-2029)
    Table 6. World Oral Drugs for Benign Prostatic Hyperplasia Production by Region (2018-2023) & (K Units)
    Table 7. World Oral Drugs for Benign Prostatic Hyperplasia Production by Region (2024-2029) & (K Units)
    Table 8. World Oral Drugs for Benign Prostatic Hyperplasia Production Market Share by Region (2018-2023)
    Table 9. World Oral Drugs for Benign Prostatic Hyperplasia Production Market Share by Region (2024-2029)
    Table 10. World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Region (2018-2023) & (US$/Unit)
    Table 11. World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Region (2024-2029) & (US$/Unit)
    Table 12. Oral Drugs for Benign Prostatic Hyperplasia Major Market Trends
    Table 13. World Oral Drugs for Benign Prostatic Hyperplasia Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
    Table 14. World Oral Drugs for Benign Prostatic Hyperplasia Consumption by Region (2018-2023) & (K Units)
    Table 15. World Oral Drugs for Benign Prostatic Hyperplasia Consumption Forecast by Region (2024-2029) & (K Units)
    Table 16. World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Manufacturer (2018-2023) & (USD Million)
    Table 17. Production Value Market Share of Key Oral Drugs for Benign Prostatic Hyperplasia Producers in 2022
    Table 18. World Oral Drugs for Benign Prostatic Hyperplasia Production by Manufacturer (2018-2023) & (K Units)
    Table 19. Production Market Share of Key Oral Drugs for Benign Prostatic Hyperplasia Producers in 2022
    Table 20. World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Manufacturer (2018-2023) & (US$/Unit)
    Table 21. Global Oral Drugs for Benign Prostatic Hyperplasia Company Evaluation Quadrant
    Table 22. World Oral Drugs for Benign Prostatic Hyperplasia Industry Rank of Major Manufacturers, Based on Production Value in 2022
    Table 23. Head Office and Oral Drugs for Benign Prostatic Hyperplasia Production Site of Key Manufacturer
    Table 24. Oral Drugs for Benign Prostatic Hyperplasia Market: Company Product Type Footprint
    Table 25. Oral Drugs for Benign Prostatic Hyperplasia Market: Company Product Application Footprint
    Table 26. Oral Drugs for Benign Prostatic Hyperplasia Competitive Factors
    Table 27. Oral Drugs for Benign Prostatic Hyperplasia New Entrant and Capacity Expansion Plans
    Table 28. Oral Drugs for Benign Prostatic Hyperplasia Mergers & Acquisitions Activity
    Table 29. United States VS China Oral Drugs for Benign Prostatic Hyperplasia Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 30. United States VS China Oral Drugs for Benign Prostatic Hyperplasia Production Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 31. United States VS China Oral Drugs for Benign Prostatic Hyperplasia Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
    Table 32. United States Based Oral Drugs for Benign Prostatic Hyperplasia Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Value, (2018-2023) & (USD Million)
    Table 34. United States Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Value Market Share (2018-2023)
    Table 35. United States Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2023) & (K Units)
    Table 36. United States Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Market Share (2018-2023)
    Table 37. China Based Oral Drugs for Benign Prostatic Hyperplasia Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Value, (2018-2023) & (USD Million)
    Table 39. China Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Value Market Share (2018-2023)
    Table 40. China Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2023) & (K Units)
    Table 41. China Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Market Share (2018-2023)
    Table 42. Rest of World Based Oral Drugs for Benign Prostatic Hyperplasia Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Value, (2018-2023) & (USD Million)
    Table 44. Rest of World Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Value Market Share (2018-2023)
    Table 45. Rest of World Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2023) & (K Units)
    Table 46. Rest of World Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Market Share (2018-2023)
    Table 47. World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 48. World Oral Drugs for Benign Prostatic Hyperplasia Production by Type (2018-2023) & (K Units)
    Table 49. World Oral Drugs for Benign Prostatic Hyperplasia Production by Type (2024-2029) & (K Units)
    Table 50. World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Type (2018-2023) & (USD Million)
    Table 51. World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Type (2024-2029) & (USD Million)
    Table 52. World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Type (2018-2023) & (US$/Unit)
    Table 53. World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Type (2024-2029) & (US$/Unit)
    Table 54. World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 55. World Oral Drugs for Benign Prostatic Hyperplasia Production by Application (2018-2023) & (K Units)
    Table 56. World Oral Drugs for Benign Prostatic Hyperplasia Production by Application (2024-2029) & (K Units)
    Table 57. World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Application (2018-2023) & (USD Million)
    Table 58. World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Application (2024-2029) & (USD Million)
    Table 59. World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Application (2018-2023) & (US$/Unit)
    Table 60. World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Application (2024-2029) & (US$/Unit)
    Table 61. Eli Lilly Basic Information, Manufacturing Base and Competitors
    Table 62. Eli Lilly Major Business
    Table 63. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 64. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 65. Eli Lilly Recent Developments/Updates
    Table 66. Eli Lilly Competitive Strengths & Weaknesses
    Table 67. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
    Table 68. GlaxoSmithKline Major Business
    Table 69. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 70. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 71. GlaxoSmithKline Recent Developments/Updates
    Table 72. GlaxoSmithKline Competitive Strengths & Weaknesses
    Table 73. Astellas Pharma Basic Information, Manufacturing Base and Competitors
    Table 74. Astellas Pharma Major Business
    Table 75. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 76. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 77. Astellas Pharma Recent Developments/Updates
    Table 78. Astellas Pharma Competitive Strengths & Weaknesses
    Table 79. Sanofi Basic Information, Manufacturing Base and Competitors
    Table 80. Sanofi Major Business
    Table 81. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 82. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 83. Sanofi Recent Developments/Updates
    Table 84. Sanofi Competitive Strengths & Weaknesses
    Table 85. Pfizer Basic Information, Manufacturing Base and Competitors
    Table 86. Pfizer Major Business
    Table 87. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 88. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 89. Pfizer Recent Developments/Updates
    Table 90. Pfizer Competitive Strengths & Weaknesses
    Table 91. Abbott Basic Information, Manufacturing Base and Competitors
    Table 92. Abbott Major Business
    Table 93. Abbott Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 94. Abbott Oral Drugs for Benign Prostatic Hyperplasia Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 95. Abbott Recent Developments/Updates
    Table 96. Abbott Competitive Strengths & Weaknesses
    Table 97. Allergan Basic Information, Manufacturing Base and Competitors
    Table 98. Allergan Major Business
    Table 99. Allergan Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 100. Allergan Oral Drugs for Benign Prostatic Hyperplasia Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 101. Allergan Recent Developments/Updates
    Table 102. Allergan Competitive Strengths & Weaknesses
    Table 103. TEVA Basic Information, Manufacturing Base and Competitors
    Table 104. TEVA Major Business
    Table 105. TEVA Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 106. TEVA Oral Drugs for Benign Prostatic Hyperplasia Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 107. TEVA Recent Developments/Updates
    Table 108. TEVA Competitive Strengths & Weaknesses
    Table 109. Viatris Basic Information, Manufacturing Base and Competitors
    Table 110. Viatris Major Business
    Table 111. Viatris Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 112. Viatris Oral Drugs for Benign Prostatic Hyperplasia Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 113. Viatris Recent Developments/Updates
    Table 114. Viatris Competitive Strengths & Weaknesses
    Table 115. Novartis Basic Information, Manufacturing Base and Competitors
    Table 116. Novartis Major Business
    Table 117. Novartis Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 118. Novartis Oral Drugs for Benign Prostatic Hyperplasia Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 119. Novartis Recent Developments/Updates
    Table 120. Merck Basic Information, Manufacturing Base and Competitors
    Table 121. Merck Major Business
    Table 122. Merck Oral Drugs for Benign Prostatic Hyperplasia Product and Services
    Table 123. Merck Oral Drugs for Benign Prostatic Hyperplasia Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 124. Global Key Players of Oral Drugs for Benign Prostatic Hyperplasia Upstream (Raw Materials)
    Table 125. Oral Drugs for Benign Prostatic Hyperplasia Typical Customers
    Table 126. Oral Drugs for Benign Prostatic Hyperplasia Typical Distributors
List of Figure
    Figure 1. Oral Drugs for Benign Prostatic Hyperplasia Picture
    Figure 2. World Oral Drugs for Benign Prostatic Hyperplasia Production Value: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Oral Drugs for Benign Prostatic Hyperplasia Production Value and Forecast (2018-2029) & (USD Million)
    Figure 4. World Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2029) & (K Units)
    Figure 5. World Oral Drugs for Benign Prostatic Hyperplasia Average Price (2018-2029) & (US$/Unit)
    Figure 6. World Oral Drugs for Benign Prostatic Hyperplasia Production Value Market Share by Region (2018-2029)
    Figure 7. World Oral Drugs for Benign Prostatic Hyperplasia Production Market Share by Region (2018-2029)
    Figure 8. North America Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2029) & (K Units)
    Figure 9. Europe Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2029) & (K Units)
    Figure 10. China Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2029) & (K Units)
    Figure 11. Japan Oral Drugs for Benign Prostatic Hyperplasia Production (2018-2029) & (K Units)
    Figure 12. Oral Drugs for Benign Prostatic Hyperplasia Market Drivers
    Figure 13. Factors Affecting Demand
    Figure 14. World Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029) & (K Units)
    Figure 15. World Oral Drugs for Benign Prostatic Hyperplasia Consumption Market Share by Region (2018-2029)
    Figure 16. United States Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029) & (K Units)
    Figure 17. China Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029) & (K Units)
    Figure 18. Europe Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029) & (K Units)
    Figure 19. Japan Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029) & (K Units)
    Figure 20. South Korea Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029) & (K Units)
    Figure 21. ASEAN Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029) & (K Units)
    Figure 22. India Oral Drugs for Benign Prostatic Hyperplasia Consumption (2018-2029) & (K Units)
    Figure 23. Producer Shipments of Oral Drugs for Benign Prostatic Hyperplasia by Manufacturer Revenue ($MM) and Market Share (%): 2022
    Figure 24. Global Four-firm Concentration Ratios (CR4) for Oral Drugs for Benign Prostatic Hyperplasia Markets in 2022
    Figure 25. Global Four-firm Concentration Ratios (CR8) for Oral Drugs for Benign Prostatic Hyperplasia Markets in 2022
    Figure 26. United States VS China: Oral Drugs for Benign Prostatic Hyperplasia Production Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 27. United States VS China: Oral Drugs for Benign Prostatic Hyperplasia Production Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Oral Drugs for Benign Prostatic Hyperplasia Consumption Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. United States Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Market Share 2022
    Figure 30. China Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Market Share 2022
    Figure 31. Rest of World Based Manufacturers Oral Drugs for Benign Prostatic Hyperplasia Production Market Share 2022
    Figure 32. World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 33. World Oral Drugs for Benign Prostatic Hyperplasia Production Value Market Share by Type in 2022
    Figure 34. Alpha Blockers
    Figure 35. 5-alpha Reductase Inhibitors
    Figure 36. Others
    Figure 37. World Oral Drugs for Benign Prostatic Hyperplasia Production Market Share by Type (2018-2029)
    Figure 38. World Oral Drugs for Benign Prostatic Hyperplasia Production Value Market Share by Type (2018-2029)
    Figure 39. World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Type (2018-2029) & (US$/Unit)
    Figure 40. World Oral Drugs for Benign Prostatic Hyperplasia Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 41. World Oral Drugs for Benign Prostatic Hyperplasia Production Value Market Share by Application in 2022
    Figure 42. Hospitals
    Figure 43. Drugstores
    Figure 44. Others
    Figure 45. World Oral Drugs for Benign Prostatic Hyperplasia Production Market Share by Application (2018-2029)
    Figure 46. World Oral Drugs for Benign Prostatic Hyperplasia Production Value Market Share by Application (2018-2029)
    Figure 47. World Oral Drugs for Benign Prostatic Hyperplasia Average Price by Application (2018-2029) & (US$/Unit)
    Figure 48. Oral Drugs for Benign Prostatic Hyperplasia Industry Chain
    Figure 49. Oral Drugs for Benign Prostatic Hyperplasia Procurement Model
    Figure 50. Oral Drugs for Benign Prostatic Hyperplasia Sales Model
    Figure 51. Oral Drugs for Benign Prostatic Hyperplasia Sales Channels, Direct Sales, and Distribution
    Figure 52. Methodology
    Figure 53. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global Oral Drugs for Benign Prostatic Hyperplasia Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Oral Drugs for Benign Prostatic Hyperplasia Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 06 Feb 2023

date Pharma & Healthcare

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

Global Oral Drugs for Benign Prostatic Hyperplasia Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Oral Drugs for Benign Prostatic Hyperplasia Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 05 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Oral Drugs for Benign Prostatic Hyperplasia market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Global Oral Drugs for Benign Prostatic Hyperplasia Supply, Demand and Key Producers, 2024-2030

Global Oral Drugs for Benign Prostatic Hyperplasia Supply, Demand and Key Producers, 2024-2030

date 25 Feb 2024

date Pharma & Healthcare

The global Oral Drugs for Benign Prostatic Hyperplasia market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

Product Tags

Oral Drugs for Benign Prostatic Hyperplasia

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>